T2 Biosystems, Inc.

T2 Biosystems, Inc.'s next confirmed earnings release is scheduled for November 13, 2026.

As of September 30, 2024, T2 Biosystems, Inc. has 18.76M shares outstanding.

As of September 30, 2024, T2 Biosystems, Inc. maintains a current ratio of 0.40, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -161.78, indicating conservative leverage, while an interest coverage ratio of -12.98 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -140.00, reflecting losses generated across the asset base. The company generates approximately 67,938.05 in revenue per employee across its workforce of 113.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.35 indicates how many times T2 Biosystems, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, T2 Biosystems, Inc.'s stock has declined approximately 95.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Over the twelve months ended September 30, 2024, T2 Biosystems, Inc. generated 7.68M in revenue and converted that into -42.95M in net income, yielding earnings per share of -4.18. EBITDA reached -41.40M, while operating income came in at -41.65M.

As of September 30, 2024, T2 Biosystems, Inc. holds 2.08M in cash and equivalents against 18.94M in total debt, resulting in a net debt position of 9.84M. Total book value stands at -11.71M, with working capital of -14.65M providing operational flexibility.

T2 Biosystems, Inc. produced -36.59M in operating cash flow over the twelve months ended September 30, 2024. After subtracting -26,000.00 in capital expenditures, free cash flow totaled -36.62M - equivalent to -3.56 per share.

Over the twelve months ended September 30, 2024, T2 Biosystems, Inc. posted a gross margin of -76.76, reflecting its pricing power and cost economics. The operating margin of -542.59 and net profit margin of -559.52 provide insight into operational efficiency.

T2 Biosystems, Inc.'s most recent stock split took place on October 13, 2023 with a 100:1 split ratio.